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Abstract
In June 2014, the H3Africa Working Group on Ethics organised a workshop with members of over 40 research
ethics committees from across Africa to discuss the ethical challenges raised in H3Africa research, and to receive
input on the proposed H3Africa governance framework. Prominent amongst a myriad of ethical issues raised by
meeting participants were concerns over consent for future use of samples and data, the role of community
engagement in large international collaborative projects, and particular features of the governance of sample
sharing. This report describes these concerns in detail and will be informative to researchers wishing to conduct
genomic research on diseases pertinent to the African research context.
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Introduction
Genomic research in Africa raises a number of unique
ethical challenges, arising most prominently from the
interplay between vanguard science and traditional com-
munities and research contexts. H3Africa research, which
seeks to foster genomic research on diseases pertinent to
African people, needs to carefully consider these ethical
challenges. In June 2014, the H3Africa Working Group on
Ethics convened a consultative meeting with members of
research ethics committees (RECs) from across Africa to
discuss ethical challenges in H3Africa research, with par-
ticular focus on issues relating to broad consent, sample
and data sharing. H3Africa is an international collabor-
ation of scientists working to build genomic research cap-
acity in Africa (H3Africa Consortium 2014). The goal is to
support cutting edge research to advance understanding
of the genetic and environmental determinants of com-
mon diseases in Africa and to use this knowledge to im-
prove the health of African populations. A key component
of H3Africa research is the global sharing of data and se-
lected biospecimens to promote their utility and to speed
up discovery of new knowledge that could impact disease
prevention and management. This raises a number of key
ethical considerations that need to be addressed in order
for H3Africa research to be successful. To better under-
stand these issues and the perspectives of research ethics
committees on H3Africa research, the H3Africa Working
Group on Ethics hosted a consultation meeting to which
we invited the Chairs of research ethics committees in-
volved in the review of H3Africa projects. The meeting
was attended by just over 80 people including 60 members
of 40 research ethics committees from 18 African coun-
tries.1 Also in attendance were a number of H3Africa re-
searchers, members of the H3Africa Working Group on
Ethics, and representatives of the two funding agencies
that are supporting H3Africa research; the US National
Institutes of Health and the Wellcome Trust. In this re-
port, we share the main lessons learnt from this consult-
ation meeting.
Broad consent
Much of the days’ discussion focussed on consent in
general and consent for genomic research specifically.
Meeting participants referred to traditional knowledge
about inheritance – for instance, that particular disease
traits are more common in some families – as a way to
explain genomic research. The most pertinent topic of
discussion, however, related to consent for sample sharing
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and biobanking. The proposal is that H3Africa samples will
be deposited in one of four H3Africa Biorepositories –
based on the African continent – for onward distribution
to the scientific community. Similarly, and in line with
international standards, genomic data will be deposited in
data repositories for secondary use. From a scientific and
funder perspective, it is recommended that H3Africa sam-
ples and data are collected with broad consent to allow for
the sharing of genomic and phenotype data as well as hu-
man samples (see for instance the H3Africa Guidelines on
Informed Consent, www.h3africa.org). In the H3Africa
Guidelines on Informed Consent, broad consent means
consent that allows use of samples and genomic and
phenotype data for future research with ethics approval
and the possibility to withdraw. In the scientific genomic
community, this sort of consent is commonly referred to
as ‘broad consent’. As the presentations and discussions
ensued it became apparent that this definition was not
shared by the workshop participants who alternately spoke
of ‘open’, ‘blanket’ and ‘unrestricted’ consent. In the under-
standing of the H3Africa Working Group on Ethics, these
latter terms refer to consent that does not place any limi-
tations on the kinds of research that samples and data can
be used for in future and whereby secondary use takes
place without ethics approval. Consent without limitations
was considered to possibly be unethical by many of
the meeting participants because it would not consti-
tute ‘informed’ consent. The term broad consent in
the bioethics community indicates consent to a wide
range of research topics, including for instance to bio-
medical, genomic, and population genetics research
projects, that have ethics approval. Broad consent does
not imply that samples and data can be used for abso-
lutely anything. Meeting participants felt that consent
that allows for some future use could be permissible
in the African research context, providing that it is
valid and clearly understood. By ‘African research con-
text’ we mean a highly diverse research setting that is
characterised by often under-resourced healthcare and
research systems servicing a mixed urban and rural popu-
lation, of varying degrees of wealth, with varying degrees
of literacy and with a high burden of communicable and
non-communicable diseases and with diverse national
laws. There was concern that where valid consent is
already difficult to obtain due to poverty and low educa-
tion, as is the case in many African research contexts,
seeking ‘broad’ consent in addition to specific consent for
the primary research project poses real challenges. Some
meeting participants also suggested that research partici-
pants should have an option to refuse consent for future
use whilst being allowed to participate in the primary re-
search project. If participants do not have an option to re-
fuse sample sharing and future re-use then some of the
meeting participants felt that this could compromise the
validity of consent, particularly because people often give
consent on the basis of trust, not knowledge.
It was clear during the meeting that there is vast diver-
sity in experience between the committee members and
countries represented. For instance, the Ugandan Na-
tional Council for Science and Technology has been
using and approving broad consent for the past six
years, whereas members of the other committees indi-
cated that they had not reviewed any projects using
broad consent. Also, it became clear that within particu-
lar countries there may be legal limits to the permissibil-
ity of broad consent, and to the timeframe for storage of
samples. Following from these discussions, it is clear that
the consent requirements for projects like H3Africa that
involve the sharing of samples and data for secondary
use need to be better understood in general, and specif-
ically in the African research context. There is an urgent
need for empirical work that explores the views of a var-
iety of stakeholders to investigate what they understand
broad consent to be. There is also a need to outline the
criteria under which broad consent can (not) be used in
medical research in Africa. Such empirical work is
needed to inform both practice and policy development
in this area.
Community engagement
Quite prominent in the discussions was the role of com-
munity engagement to support both broad consent and
the governance of biobanks. Community engagement is
very important in the African research context, particu-
larly when research participants live in rural communi-
ties that are isolated from information about genomic
research and health care facilities, and that are embed-
ded in long-standing support systems and values. In
rural communities especially, the values and concerns of
the community are often considered to be at least as im-
portant as individual values prioritized in the informed
consent documents. Community engagement is one way
of considering community values in research, and is an
important step in respecting communities. The meeting
participants indicated that involvement of communities
throughout the research process – preceding and during
sample collection and in future use decisions – is of key
importance in ensuring ethical conduct in research. The
strong emphasis on community engagement, and the
proposal that communities are involved in biobank gov-
ernance in some way, is a unique feature of the African re-
search context. As a minimum, it was suggested that the
governance framework for sample and data sharing ought
to be informed by community engagement. But commu-
nity engagement raises many questions, for instance about
what constitutes a ‘community’ and who represents it, how
it can effectively be consulted and involved, and how com-
munity engagement can be evaluated. There is also a need
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to better understand the applicability of community en-
gagement long-term, for instance in biobank governance.
A particular challenge in the H3Africa context is that
H3Africa biobanks will be organised internationally, and
that samples from a multitude of communities will be
stored in them. Exactly how communities can and should
be involved in the governance of the H3Africa biobanks is
an important question that will need to be investigated.
Governance framework for biobanking research
During the meeting, the need for a good governance
framework to guide sample and data access decisions be-
came exceedingly clear. The purpose of a transparent
and robust governance framework would be to build
trust, prevent harm and maximise benefit. The frame-
work needs to address essential questions about control
over and ownership of samples and data. It would also
need to specify whether and to which extent commer-
cialisation of samples or sample products are permis-
sible. The framework would need to comply with local
and national guidelines and regulations insofar as these
exist. Guidance would have to articulate a clear mechan-
ism for withdrawal of samples and data from the biore-
pository and ensure that confidentiality is maintained
throughout the research process. Of note is the virtual
absence of guidance on biobanking research in African
jurisdictions. Many of the research ethics committee
members present at the meeting felt that they needed
such guidance to help them review project proposals in-
volving sample and data sharing. Such guidance should
specifically take into consideration the African research
context, which includes infrastructural challenges, in-
stability in governments, Africa’s colonial history and
continued use of the expertise of local medical healers
who work with plants and the spirit world within a sys-
tem that attaches symbolic value to blood and other hu-
man samples.
It was clear from the discussions that there is a need
to continue to involve the research ethics committees
that originally approved sample collection in sample
sharing decisions in some way. As a minimum, this
could be through regular reporting of the biobanking ac-
tivities. It was also proposed that research ethics com-
mittees could indicate when particularly vulnerable
population groups are involved in research and request
to be party to sample access decisions in those cases.
Also, it should be possible for the people deciding on
sample access to refer difficult secondary access pro-
posals to the original research ethics committee that ap-
proved sample collection. It became clear during the
meeting that there is a continuing need for training of
research ethics committee members in the particulars of
genomic and biobanking research.
The H3Africa Consortium has just finalised the Terms
of Reference of the H3Africa Data and Biospecimen
Access Committee (for more information see www.h3
africa.org). These terms were still under development
when the Ethics Consultation Meeting was held and they
were amended as a direct outcome of this meeting. Two
important changes were introduced: first, the terms now
stipulate mandatory regular reporting of access decisions
to the research ethics committees that approved sample
collection, and second, they introduce the possibility for
the access committee to consult with members of the re-
search ethics committee that originally approved sample
collection if and when necessary.
Conclusion and ways forward
There are multiple challenges confronting genomic re-
search in Africa and these have been highlighted in the
H3Africa Marker Paper (H3Africa Consortium 2014).
Pertinent amongst these challenges are ethical issues.
The H3Africa Ethics Consultation Meeting was a critical
step in understanding better the range of issues related
to H3Africa research, including the question “How will
Africa benefit? a point of critical importance to both
presenters and meeting participants. By engaging mem-
bers from research ethics committees and national ethics
councils from 18 countries we began a much needed
dialogue about ways to coevolve science and ethical
regulation in the African research context. In this report,
we have highlighted the most pertinent issues that were
discussed during the H3Africa Ethics Consultation
Meeting, namely challenges relating to consent, commu-
nity engagement and the governance of sample and data
access. Most clearly, the meeting established the central-
ity of trust in ensuring that H3Africa research comes to
fruition. In order for the sharing of samples and data to
be ethically acceptable in the African research context,
the research needs to be accompanied by thorough com-
munity engagement and embedded in a robust and
transparent governance framework. Samples and data
also need to be collected with valid consent. In addition
to these ethical issues, challenges were identified that are
not new to H3Africa research but that do affect it. These
were for instance issues relating to inducement, moni-
toring of approved research and how to explain complex
scientific concepts during the consent process.
H3Africa has established a Working Group on Ethics
that seeks to systematically interrogate these issues and
help develop an ethical framework for genomic research
in Africa. As a Working Group the meeting helped us
realise the value of ongoing engagement with those in-
volved in research ethics review and hope to continue
this activity. Specifically, this meeting helped the Work-
ing Group to develop a strategic workplan on informed
consent. As part of this workplan, we are analysing
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current H3Africa consent forms used by the various pro-
jects to examine the range of consent models used. We
have also sourced ethics guidelines and legislation from
a variety of African countries to examine ethical and
legal perspectives and obstacles to genomics and bio-
banking research. The Working Group also managed to
secure funding for a follow-up meeting with REC mem-
bers to specifically explore the ethical challenges around
informed consent for biobanking and genomics research.
This meeting is likely to be held in Zambia in May 2015.
Several empirical projects on informed consent are also
being conducted in several African countries.
With regards to the training of REC members in the re-
view of genomics and biobanking research, the H3Africa
Working Group Ethics has teamed up with the West
African Bioethics Network to develop a hybrid online and
in-person training course. Funding for curriculum devel-
opment has been received from the NIH and course mate-
rials are currently being developed and should become
available online in August 2015.
With regards to Community Engagement, the Working
Group has just finalised a project that sought to identify
different community engagement models that can be used
to support African genomics research. The first phase of
the project which involved a literature review was submit-
ted for publication and will hopefully be published in
2015. The second phase involved an assessment of com-
munity engagement activities taking place within H3Africa
research projects which consisted of interviews and a
questionnaire to H3Africa researchers. The results of this
project have been written up into a research report that is
being finalised by the Working Group. More information
about the work of this group, a more complete version of
these meeting proceedings and a list of meeting partici-
pants can be found at www.h3africa.org.
Endnote
aParticipants came from Benin, Botswana, Burkina
Faso, Cameroon, Cote d'Ivoire, Ethiopia, Ghana, Guinea,
Kenya, Malawi, Mali, Mozambique, Nigeria, South Africa,
Sudan, Tanzania, Uganda, Zambia.
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